Apellis Pharmaceuticals Inc
(STU:1JK)
€
25.73
-0.175 (-0.68%)
Market Cap: 3.15 Bil
Enterprise Value: 3.25 Bil
PE Ratio: 0
PB Ratio: 12.89
GF Score: 25/100 Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
Sep 16, 2022 / 08:55AM GMT
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Thank you, everybody. Hopefully, you can hear me. Good morning. Welcome to be Bank of America Healthcare Conference line from London. I'm Tazeen Ahmad. I'm one of the biotech analysts here at the firm. It is my pleasure to have our next presenting company. Sitting here with me this morning are 3 members from Apellis, CEO, Cedric Francois; Chief Commercial Officer, Adam Townsend; Chief Financial Officer, Tim Sullivan. Good morning, gentlemen and thank you for making the trip over.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Good morning. Thank you. Happy to be here.
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
So I think everyone else is saying is familiar with the company so we can skip over the intro and go straight to, I think, the main questions.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot